Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor

Ian S. Zagon, Shawn Kreiner, Jeffery J. Heslop, Andrea B. Conway, Clinton R. Morgan, Patricia J. McLaughlin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

This study examined overexpression of the opioid growth factor receptor (OGFr) in pancreatic cancer cells and phenotypic changes in tumorigenicity. Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice. No differences in OGFr binding were detected between tumors of EV and WT animals. Tumor incidence in OGFr-1 animals was reduced by up to 50% from EV mice. Latency times for OGFr-1 tumor expression were increased 30%, tumor volume was decreased 70%, and DNA synthesis was reduced 24% relative to EV mice. Exogenous OGF reduced OGFr-1 tumor volume up to 55% compared to OGFr-1 mice given vehicle. These data support OGFr gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalInternational journal of oncology
Volume33
Issue number2
DOIs
StatePublished - Aug 1 2008

Fingerprint

Pancreatic Neoplasms
Neoplasms
Tumor Burden
methionine-enkephalin receptor
Wild Animals
Complementary DNA
Cell Proliferation
Pharmacology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{d763ccaceb0f416683e9fc1a0067cfc2,
title = "Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor",
abstract = "This study examined overexpression of the opioid growth factor receptor (OGFr) in pancreatic cancer cells and phenotypic changes in tumorigenicity. Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice. No differences in OGFr binding were detected between tumors of EV and WT animals. Tumor incidence in OGFr-1 animals was reduced by up to 50{\%} from EV mice. Latency times for OGFr-1 tumor expression were increased 30{\%}, tumor volume was decreased 70{\%}, and DNA synthesis was reduced 24{\%} relative to EV mice. Exogenous OGF reduced OGFr-1 tumor volume up to 55{\%} compared to OGFr-1 mice given vehicle. These data support OGFr gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer.",
author = "Zagon, {Ian S.} and Shawn Kreiner and Heslop, {Jeffery J.} and Conway, {Andrea B.} and Morgan, {Clinton R.} and McLaughlin, {Patricia J.}",
year = "2008",
month = "8",
day = "1",
doi = "10.3892/ijo_00000011",
language = "English (US)",
volume = "33",
pages = "317--323",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. / Zagon, Ian S.; Kreiner, Shawn; Heslop, Jeffery J.; Conway, Andrea B.; Morgan, Clinton R.; McLaughlin, Patricia J.

In: International journal of oncology, Vol. 33, No. 2, 01.08.2008, p. 317-323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor

AU - Zagon, Ian S.

AU - Kreiner, Shawn

AU - Heslop, Jeffery J.

AU - Conway, Andrea B.

AU - Morgan, Clinton R.

AU - McLaughlin, Patricia J.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - This study examined overexpression of the opioid growth factor receptor (OGFr) in pancreatic cancer cells and phenotypic changes in tumorigenicity. Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice. No differences in OGFr binding were detected between tumors of EV and WT animals. Tumor incidence in OGFr-1 animals was reduced by up to 50% from EV mice. Latency times for OGFr-1 tumor expression were increased 30%, tumor volume was decreased 70%, and DNA synthesis was reduced 24% relative to EV mice. Exogenous OGF reduced OGFr-1 tumor volume up to 55% compared to OGFr-1 mice given vehicle. These data support OGFr gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer.

AB - This study examined overexpression of the opioid growth factor receptor (OGFr) in pancreatic cancer cells and phenotypic changes in tumorigenicity. Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice. No differences in OGFr binding were detected between tumors of EV and WT animals. Tumor incidence in OGFr-1 animals was reduced by up to 50% from EV mice. Latency times for OGFr-1 tumor expression were increased 30%, tumor volume was decreased 70%, and DNA synthesis was reduced 24% relative to EV mice. Exogenous OGF reduced OGFr-1 tumor volume up to 55% compared to OGFr-1 mice given vehicle. These data support OGFr gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=48749130178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749130178&partnerID=8YFLogxK

U2 - 10.3892/ijo_00000011

DO - 10.3892/ijo_00000011

M3 - Article

C2 - 18636152

AN - SCOPUS:48749130178

VL - 33

SP - 317

EP - 323

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -